Key Highlights

  • On Friday, November 6, 2026, TransMedics Group's shares were trading up 23.59% at USD 85.26, a day after third-quarter 2026 numbers and a higher Revenue forecast became public.
  • Revenue for the quarter jumped 41%, from USD 143.8 million to USD 203.0 million; excluding the PAD Aviation purchase the gain was 35%, and service sales rose 60% to USD 89.6 million.
  • Earnings declined: Net Income landed at USD 17.1 million versus USD 24.3 million, equal to USD 0.46 diluted per share against USD 0.66, while operating costs totaled USD 90.5 million.
  • Counting PAD Aviation, the 2026 revenue range is USD 764 million to USD 774 million, and quarter-end cash was USD 493.0 million as of September 30, 2026.

Top-Line Growth and Raised Guidance Versus Softer Profit

TransMedics Group (NASDAQ:TMDX) posted third-quarter results on November 5, 2026. Revenue hit USD 203.0 million, a 41% advance from USD 143.8 million. Product sales grew 29% to USD 113.4 million and service sales grew 60% to USD 89.6 million. Excluding PAD Aviation, the 2026 revenue range now reads USD 750 million to USD 760 million, replacing USD 737 million to USD 757 million. Counting the roughly USD 14 million expected from PAD Aviation brings the total to USD 764 million to USD 774 million. The shares traded much higher the following session, a move that appears to reflect growth and the higher outlook outweighing weaker earnings, though this link is an inference.

Cost Growth Accounts for the Lower Earnings Per Share

Operating income increased 21% to USD 28.1 million, but Operating Margin contracted by 230 basis points to 13.9% because costs expanded faster than sales. Research and Development surged to USD 29.2 million from USD 15.3 million, while selling, general and administrative expense climbed to USD 61.3 million from USD 46.0 million. Gross margin landed at 58.5%, compared with 58.8%. Diluted EPS came in at USD 0.46 versus USD 0.66, and adjusted EPS was USD 0.51 against USD 0.67. For the first nine months, sales advanced 27% to USD 566.9 million, while net income slid to USD 39.1 million, down from USD 84.9 million. Share-based pay totaled USD 12.1 million, compared with USD 8.7 million.

Pipeline Progress, Cash and What Remains Unresolved

Among program updates, enrollment finished in Part A of the ENHANCE Heart study, an FDA-approved continued access protocol. IDE clearances arrived for ENHANCE Heart Part B and the DENOVO Lung study, and the company secured its first European tender for transplant logistics, in Italy. Fernando Araujo was appointed chief financial officer. Cash totaled USD 493.0 million. A published data page placed the stock near USD 70.63 on October 26, against a 52-week band of USD 60.11 to USD 156.00; measured against the USD 85.26 level, the current price sits about 45% under the top of that band, a calculation built on stale, single-source figures. Cost growth, trial results and a law firm's September investigation notice, which remains unproven, all bear watching. The next report will show whether margins rebound as new programs scale.

Where Things Stand

Whether the gain holds is still open. The move seems linked to revenue expansion and a higher full-year outlook outweighing lower profit, though that is an inference. TransMedics delivered 41% growth and a higher range, while margins narrowed under heavier research and administrative spending. The share price remains far below its 52-week peak, so this rally recoups only part of an earlier slide. Upcoming markers include fourth-quarter results, how fast operating expenses grow and updates on the heart and lung programs.